Oct. 18, 2021– A new federal government report could add momentum to efforts on Capitol Hill to end limitations on 340B price discounts for orphan drugs purchased by certain safety-net hospitals. The report suggests that drug companies might be seeking orphan status for their products to maximize revenues and avoid paying 340B discounts on drugs widely used to treat common … [Read more...]
NPR and Kaiser Health News Explore 340B Orphan Drug Exclusion
September 18, 2017—National Public Radio and Kaiser Health News have collaborated on an in-depth report on how a federal law that denies rural hospitals 340B drug discounts on orphan drugs “has left rural hospital pharmacists and health care workers struggling to keep medicines in stock, and wondering if they will be able to adequately care for patients.” … [Read more...]